



Date: 17.06.2024

Methodological Note

On disclosure of Transfers of Value

- 1. Country** Germany
- 2. Company** Glenmark Arzneimittel GmbH (“Glenmark”)
- 3. Period Covered** 2023
- 4. Description** Methodological Note on disclosure of Transfers of Values made to Healthcare Professionals, Healthcare Organizations and/or Patient Organizations, following the Medicines for Europe Code of Conduct.
- 5. Scope**

The disclosure covers all Transfers of Value required to be disclosed pursuant to the Medicines for Europe Code of Conduct which have been made by Glenmark during the Period Covered to Healthcare Professionals, Healthcare Organizations and/or Patient Organisations; with regard to prescription-only medicines for human use, including innovative, generic and biosimilar products.

Fees paid in connection with research & development activities or anonymous market research are not disclosed.

Definitions of capitalized terms which are not elsewhere defined in this Methodological Note can be found in section 9 below.
- 6. Methodology**

General Methodology

Currency: Transfers of Value are disclosed in Euro. Where the initial payment has been processed in another local currency/currencies, the amount in Euro will be reported in the Transparency Report, along with the applied exchange rate.

VAT and other taxes: Disclosed amounts do not include VAT and other taxes for all reported Transfers of Value, regardless of the nature of tax (personal, tax paid forward by a Company to the relevant country’s tax authority).

Treatment related to the timing and amount of Transfers of Value Reporting for the purposes of disclosure: where an event or an activity has taken place during the reporting year, but the respective party (Healthcare Organisation, Agency, Healthcare Professional) has not yet invoiced the company, the Transfer of Value will be

reported in the calendar year when the event/meeting or activity has first taken place.

Cross-border activities: For cross-border activities, the Transfers of Value will be disclosed in the Glenmark affiliate's Transparency report of the respective recipient's primary country of practice. Where there is no local Glenmark commercial affiliate, the Transfers of Value will be reported in the initiating Glenmark company's Transparency Report.

Late recording: If after the publication of the report, Glenmark realizes that a Transfer of Value made during the Period Covered has not been disclosed, due to the fact that such has been recorded in Glenmark's books after the publication of the report, Glenmark will re-publish an updated report.

Multi-year contracts: In case of multi-year contracts, disclosure is made for the year on which the Transfer of Value is made to the relevant recipient.

Personal Data: If consent required under applicable data privacy laws and regulations has not been given by the data subject to Glenmark (or if Glenmark might have difficulties in proving such consent), the Transfer of Value is disclosed on aggregate or on pseudonimised basis, depending on the number of Healthcare Professionals. If the majority of Healthcare Professionals have not given the relevant consent (or such consent is difficult to prove), Transfers of Value are disclosed on aggregate level only.

Methodology per Category

Transfers of Value made to Patient Organisations: Glenmark discloses the amounts attributable to the following Transfer of Values which can be reasonably allocated to Patient Organizations, on an individual, named basis: (i) fees for services - the total of all honoraria for the reporting period (excluding expenses directly related to the performance of the contracted service such as travel, accommodation and meals) with a brief description of the nature of the services provided; and (ii) financial and in-kind support in the forms of grants, donations and sponsorship of activities and events – the total contributions for the reporting period with a brief description of the nature of the support.

Transfers of Value made to Healthcare Professionals for provided services: Glenmark discloses, on an individual, named basis (unless the healthcare professional refuses consent for disclosure), the total of all honoraria for the reporting period attributable to fees for services (excluding expenses directly related to performance of the contracted service such as travel, accommodation and meals), which can be reasonably allocated to Healthcare Professionals for the provision of services, such as consultancy services.

Transfers of Value related to meetings, educational support and site visits: Glenmark discloses Transfers of Value in this category as per 7.4.8.2 Option 2 of the Medicines for Europe Code of Conduct. This is: – disclosing the total cost of each specific meeting, and the total number of healthcare professionals supported to attend, without naming the delegates. For each meeting, the following will be disclosed: the name of the congress, meeting or site visit, the total spent on registration fees, travel and accommodation for all healthcare professionals and the number of healthcare professionals financially supported to attend.

Transfers of Value to Healthcare Organisations: For the following sub-categories, Glenmark discloses Transfers of Value as follows, on an individual, named basis: (a) for fees for services: for each healthcare organisation the total of all honoraria for the reporting period (excluding expenses directly related to performance of the contracted service such as meals and drinks, travel and accommodation) paid by Glenmark to a Healthcare Organisation in exchange for the provision of services; and (b) for grants and donations: for each healthcare organisation the total of all contributions in the reporting period made in accordance with clause 6.7 of the Medicines for Europe Code of Conduct.

7. Method of disclosure

Disclosure will be made via the company's website <https://www.glenmark.de/>

8. Time of disclosure

If disclosed on Glenmark's website, the Transfers of Value report will be accessible online (via the link mentioned in section 7 above) at least one (1) year as of the date of its publication unless local laws or regulations require longer retention period.

9. Definitions

Glenmark means the company indicated in section 2 of this Methodological Note;

Country shall mean the relevant country indicated in section 1 of this Methodological Note;

Healthcare Organisation A healthcare, medical or scientific association or organisation (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution, or learned society. Also, any entity through which one or more Healthcare Professionals provide healthcare services. For the avoidance of doubt, wholesalers, distributors, and similar commercial intermediaries are not considered Healthcare Organizations;

Healthcare Professional A member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of their professional activities, may prescribe, dispense, purchase, supply, recommend or administer a medicinal product. It includes any official or employee of a government agency or other organisation (whether in the public or private sector) who may purchase, supply, recommend or administer medicinal products. It also includes any employee of a pharmaceutical company whose primary occupation is that of a practicing healthcare professional. It excludes other employees of pharmaceutical companies, and wholesalers or distributors of medicinal products.

Medicines for Europe Code of Conduct means the Medicines for Europe Code of Conduct on Interactions with the Healthcare Community, as amended in January 2022;

Patient Organisation is a not-for-profit organisation which is patient-focused, and in which patients or their caretakers form a majority of the governing body;

Period Covered means the year indicated in section 3 of this Methodological Note;

Europe for the purposes of the Medicines for Europe Code of Conduct means the member states of the EU and EFTA as well as Albania, Bosnia-Herzegovina, Kosovo, Macedonia, Montenegro, Serbia and the United Kingdom;

Transfer of Value is anything of value, including monetary payments or in-kind benefits, that is provided to a recipient by a company, either directly or via an intermediary.

Disclosure of Transfer of Value

1. **Transfer of Value made to Patient Organisations**

No transfers of value were made to the patient organisations in 2023.
2. **Transfers of Value made to Healthcare Professionals for provided services**

No services (including consultancy services) were provided by healthcare professionals to Glenmark in 2023.
3. **Transfers of Value related to meetings, educational support and site visits**

Meetings: Glenmark has not funded any healthcare professional’s hotel accommodation and / or airplane travel in relation to meetings.

Educational Supports: No educational supports have been made in 2023.

Site visits: No site visits to Glenmark have been made by healthcare professionals during 2023.
4. **Transfer of Value to Healthcare Organisations**

Fees for services and consultancy One service has been provided by healthcare organisations to Glenmark. Therefore, fees / honoraria have been paid to the healthcare organisation for the provision of services during 2023.

Organisation	Type	Quantity	Description
CRM Centrum für Reisemedizin GmbH	Fees for other services	4500,00€	Sponsoring the event (25. Forum für Reisen und Gesundheit)

Grants and donations No donations have been made to a healthcare organisation during 2023. No grants have been made to healthcare organisations during 2023.
5. **Methodology used for disclosure**

Please see our Methodological Note on Disclosure of Transfers of Value dated on 17/06/2024.